![Darin Lippoldt](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Darin Lippoldt
President bij
SOLENO THERAPEUTICS, INC.
Vermogen: 9 M $ op 31-05-2026
Profiel
Darin Michael Lippoldt is currently President, Secretary & Director at Soleno Therapeutics, Inc. since 2026.
He is also Director at Immedica Group Ltd. since 2022 and Secretary & Chief Legal Officer at Neurocrine Biosciences, Inc. since 2014.
Formerly, Mr. Lippoldt was Associate General Counsel at Amylin Pharmaceuticals, Inc. from 2003 to 2010.
From 2013 to 2014, served as Secretary, Chief Compliance Officer & Executive VP at Philips Image Guided Therapy Corp.
Education includes undergraduate and graduate degrees from St. Mary's University, with the undergraduate degree conferred in 1987.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 13-02-2026 | 54.729 ( 0,05% ) | 9 M $ | 31-05-2026 |
Actieve functies van Darin Lippoldt
| Bedrijven | Functie | Begin |
|---|---|---|
| NEUROCRINE BIOSCIENCES, INC. | Algemeen Adviseur | 01-10-2014 |
| DIUL GROUP | Directeur/Bestuurslid | 01-11-2022 |
| SOLENO THERAPEUTICS, INC. | President | 15-05-2026 |
Eerdere bekende functies van Darin Lippoldt
| Bedrijven | Functie | Einde |
|---|---|---|
| VOLCANO CORPORATION | Compliance Officer | 01-10-2014 |
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes medicines for diabetes, obesity and cardiovascular diseases | Corporate Officer/Principal | 01-07-2010 |
Opleiding van Darin Lippoldt
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
64
Eerstegraads connecties
6
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 6 |
|---|---|
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes medicines for diabetes, obesity and cardiovascular diseases | Health Technology |
Neurocrine Biosciences, Inc.
 Neurocrine Biosciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes treatments for neurological, neuroendocrine and neuropsychiatric disorders | Health Technology |
Philips Image Guided Therapy Corp.
 Philips Image Guided Therapy Corp. Medical SpecialtiesHealth Technology Designs, develops and manufactures intravascular ultrasound products | Health Technology |
Soleno Therapeutics, Inc.
 Soleno Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops and commercializes novel therapeutics for the treatment of rare diseases | Health Technology |
St. Mary's University
 St. Mary's University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Diurnal Group Ltd.
 Diurnal Group Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and commercializes therapeutics for neuropsychiatric, neurological & neuroendocrine disorders | Health Technology |
